^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr del(9p) + PD-L1 overexpression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over1year
    Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer. (IASLC-TTLC 2023)
    Multiplexed immunofluorescence demonstrated that tumors with either high FAA levels or chromosome 9p loss had significantly fewer tumor-associated immune cells. CONCLUSION NSCLCs with high aneuploidy and chromosome 9p loss have a distinct tumor immune microenvironment and less favorable outcomes to ICIs.
    Clinical • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • PD-L1 overexpression • BRAF mutation • MET mutation • RET rearrangement • Chr del(9p) + PD-L1 overexpression